PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT COMMUNICATION / ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT COMMUNICATION / ATTORNEY WORK PRODUCT
CALDERWOOD & HARKNESS LLP Tax Department
October 1, 2022
MEMORANDUM
FROM: Leonard Cross, Responsible Partner, Tax Department, Calderwood & Harkness LLP Sylvia Hartwell, Billing Partner, Tax Department, Calderwood & Harkness LLP
TO: Marcus Whitfield, Vice President, Global Tax, Penterra Pharmaceuticals Corp. Deborah Staines, General Counsel, Penterra Pharmaceuticals Corp. Rajesh Iyer, Chief Financial Officer, Penterra Pharmaceuticals Corp.
RE: Matter Status Report — Q3 2022 IRS Transfer Pricing Examination Defense Penterra Pharmaceuticals Corp. (TY 2017–2020)
Matter Number: 1018-00009 IRS Exam Team ID: LB&I-NE-TP-2022-00641 Taxpayer EIN: 22-3741856
This memorandum is a privileged and confidential attorney-client communication and constitutes attorney work product prepared in anticipation of litigation. This memorandum is intended solely for the use of the addressees identified above and authorized representatives of Penterra Pharmaceuticals Corp. This memorandum should not be disclosed, distributed, or reproduced in whole or in part to any person or entity without the prior written consent of Calderwood & Harkness LLP. Disclosure of this memorandum to any third party may constitute a waiver of applicable privileges.
Right-click to update Table of Contents
I. EXECUTIVE SUMMARY
This memorandum provides a comprehensive status report on the activities undertaken during the third quarter of 2022 (July 1, 2022 through September 30, 2022) in connection with the ongoing Internal Revenue Service Large Business & International Division ("LB&I") examination of Penterra Pharmaceuticals Corp.'s ("PPC" or the "Company") transfer pricing positions for tax years 2017 through 2020. This report is the first quarterly status report issued since Calderwood & Harkness LLP ("C&H") was formally engaged to represent PPC in this matter.
As background, the IRS notified PPC of the opening of the examination on May 16, 2022. C&H's engagement letter with PPC was executed on June 2, 2022, and the firm promptly undertook the necessary steps to establish representation before the IRS. IRS Form 2848 (Power of Attorney and Declaration of Representative) was filed with the IRS on June 8, 2022, designating Leonard Cross, Sylvia Hartwell, Garrett Simmons, and Leila Nazari as authorized representatives of PPC for the examination. Concurrently, a Kovel engagement letter with Whitmore Valuation Group LLC ("Whitmore" or "WVG") was executed on June 20, 2022, to ensure that the independent economic analyses prepared by Whitmore in support of PPC's defense would be protected under the attorney-client privilege and the work-product doctrine. The opening conference with the IRS examination team was held on June 28, 2022, and was attended by Mr. Cross and Mr. Simmons from C&H, Mr. Whitfield from PPC, and Supervisory Revenue Agent Gerald Meskill and Lead Revenue Agent Patricia Dunleavy from the IRS.
During Q3 2022, the examination has been in the active Information Document Request ("IDR") response phase. The IRS has issued a substantial volume of IDRs during this period, reflecting the breadth of the examination and the complexity of PPC's international tax structure. In total, IDRs numbered 1 through 12 have been issued as of September 30, 2022. C&H has coordinated timely and comprehensive responses to IDRs 1 through 10, with work in progress on IDRs 11 and 12. In preparing these responses, C&H has worked closely with PPC's internal tax and finance teams, with Crestfield & Associates LLP ("Crestfield"), PPC's independent auditor and the original preparer of PPC's contemporaneous transfer pricing documentation, and with Thornbury & Keogh ("T&K"), the Irish tax advisors to Penterra Biopharma International DAC ("PBI") and Penterra Manufacturing Ireland Ltd. ("PMI").
In parallel with the IDR response effort, C&H has directed Whitmore Valuation Group to commence a suite of independent economic analyses designed to support PPC's transfer pricing positions. These analyses include a comparable uncontrolled transaction ("CUT") analysis of the legacy IP royalty rate, a comparable profits method / transactional net margin method ("CPM/TNMM") analysis of PBI's operating margins, and a platform contribution transaction ("PCT") / Discounted cash flow ("DCF") revaluation of the PCT payment. These analyses are being prepared under the Kovel arrangement to preserve privilege protections.
Additionally, C&H's legal research team has completed several key memoranda during the quarter, addressing core legal issues including the IRC § 482 arm's-length standard and best method rule, qualified cost-sharing arrangement requirements under Treasury Regulation § 1.482-7, arm's-length royalty rate standards under Treasury Regulation § 1.482-4, the economic substance doctrine and the DEMPE functions framework, the impact of the Tax Cuts and Jobs Act ("TCJA") on PPC's transfer pricing exposure, IRC § 6662(e) penalty protection and reasonable cause defense standards, applicable case law from the Altera and Harborview Corporation decisions, and IRC § 367(d) outbound IP transfer considerations.
Overall Assessment. The examination is proceeding as anticipated. The IRS examination team, led by Revenue Agent Patricia Dunleavy and supervised by Revenue Agent Gerald Meskill, has focused its initial information requests on PPC's corporate structure, the cost-sharing arrangement, the legacy IP license agreement, the PCT valuation, PBI personnel and governance, and product-level revenue data. The presence of IRS Economist Dr. Alan Washburne on the examination team confirms that the IRS is conducting its own independent economic analysis of PPC's transfer pricing positions. IRS Office of Chief Counsel Attorney-Advisor Franklin Rosario has also been identified as part of the team, suggesting the IRS is building a coordinated legal and economic case.
No proposed adjustments or Notice of Proposed Adjustment ("NOPA") have been issued at this time. Based on the current pace of IDR issuance and the typical timeline for large-case transfer pricing examinations of this nature, we do not anticipate a NOPA until mid-to-late 2023. We continue to believe that PPC's transfer pricing positions are defensible and well-supported by contemporaneous documentation, and we are strengthening the defense through independent economic analysis and comprehensive legal research.
II. EXAMINATION OVERVIEW AND BACKGROUND
A. Taxpayer Information
Penterra Pharmaceuticals Corp. is a Delaware corporation publicly traded on the Nasdaq Stock Market under the ticker symbol PPCA. PPC's principal offices are located at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. For fiscal year 2020, PPC reported consolidated revenue of approximately $6.82 billion, pre-tax income of approximately $1.47 billion, and employed approximately 14,500 individuals globally. PPC is a specialty pharmaceuticals and biotechnology company focused on oncology, immunology, and rare-disease therapeutics.
PPC is the parent company of a global group of affiliated entities that together develop, manufacture, and commercialize pharmaceutical products worldwide. The Company's principal revenue-generating products include Veritaxol (an oncology biologic), Imvara (an immunology therapy), and Cerulon (a rare-disease therapeutic), each of which is commercialized through a combination of direct sales in the Americas territory and through PPC's Irish affiliates for non-Americas territories.
B. Tax Years Under Examination
The IRS examination covers PPC's federal income tax returns (Forms 1120) for tax years 2017, 2018, 2019, and 2020. The examination spans both the pre-TCJA regime (TY 2017, at a 35% corporate rate) and the post-TCJA regime (TY 2018–2020, at a 21% corporate rate, with the addition of the Global Intangible Low-Taxed Income ("GILTI") provisions under IRC § 951A and the Base Erosion and Anti-Abuse Tax ("BEAT") under IRC § 59A). The dual-regime nature of the examination period adds complexity to both the IRS's potential adjustment calculations and PPC's defense strategy.
C. Subject Matter of the Examination
The primary focus of the IRS examination is on the transfer pricing methodology employed in connection with PPC's Irish IP-holding structure. Specifically, the IRS is examining: (i) the qualified cost-sharing arrangement between PPC and PBI, including PBI's cost-sharing percentages and the methodology used to compute reasonably anticipated benefit shares; (ii) the legacy IP royalty arrangement between PPC and PBI, under which PBI pays a royalty of 4.5% of net sales for non-Americas territory use of legacy pharmaceutical compounds; (iii) the PCT valuation of $312 million paid by PBI upon entry into the CSA for the rights to existing intangible property as of the CSA's effective date; and (iv) the economic substance and functional profile of PBI as the Irish IP-holding company.
D. Key Entities in the Corporate Structure
The following entities are central to the examination:
Penterra Pharmaceuticals Corp. ("PPC"): The U.S. parent corporation, incorporated in Delaware. PPC is the principal developer and commercializer of pharmaceutical products in the Americas territory. PPC conducts the majority of its research and development activities in the United States through its laboratories and research facilities in Princeton Junction, New Jersey, and San Diego, California. PPC holds the U.S. parent interest in the CSA and is the licensor under the legacy IP license agreement.
Penterra Holdings Luxembourg S.à r.l. ("PHL"): An intermediate holding company organized under the laws of Luxembourg, registered at 14, rue Aldringen, L-1118 Luxembourg (Luxembourg Register of Commerce and Companies No. B 168452). PHL is treated as a disregarded entity for U.S. federal income tax purposes and serves as the direct holding company for PBI. PPC owns 100% of PHL's equity interests.
Penterra Biopharma International DAC ("PBI"): An Irish designated activity company and the principal IP-holding entity for non-Americas operations. PBI is registered at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland (Irish Tax Reference No. 3218764T). PBI was incorporated on March 15, 2012, and entered into the CSA with PPC effective July 1, 2012. At that time, PBI made a PCT payment of $312 million to PPC for PBI's interest in pre-existing intangible property covered by the CSA. PBI's workforce has grown from 52 employees in 2012 to 185 employees as of year-end 2020. PBI manages all non-Americas commercialization activities, including regulatory affairs, medical affairs, commercial strategy, pricing, and market access across 68 country markets outside the Americas. For fiscal year 2020, PBI reported revenue of approximately €2.14 billion and pre-tax income of approximately €1.06 billion. Beginning in fiscal year 2016, PBI has claimed benefits under Ireland's Knowledge Development box ("KDB") regime, which provides for an effective tax rate of 6.25% on qualifying income derived from qualifying intellectual property assets. Income not qualifying for the KDB is taxed at the standard Irish trading rate of 12.5%.
Penterra Manufacturing Ireland Ltd. ("PMI"): An Irish limited company and contract manufacturer for PBI. PMI is registered at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland (Companies Registration Office No. 512347). PMI employs approximately 620 personnel and operates under a contract manufacturing agreement with PBI on a cost-plus 8% basis, producing oncology and immunology biologics for non-Americas markets.
E. IRS Examination Team
The IRS examination is being conducted by the LB&I Northeast Transfer Pricing Practice. The examination team comprises the following individuals:
•  Supervisory Revenue Agent Gerald Meskill — Team Manager
•  Lead Revenue Agent Patricia Dunleavy — Lead Examiner
•  Dr. Alan Washburne — IRS Economist, IRS Transfer Pricing Practice
•  Franklin Rosario — Attorney-Advisor, IRS Office of Chief Counsel (supervised by Senior Counsel Donna Hirabayashi)
The composition of the examination team — which includes both a dedicated IRS economist and a Chief Counsel attorney — reflects the significance the IRS attaches to this examination and confirms that the IRS is pursuing a coordinated legal and economic challenge to PPC's transfer pricing positions.
F. Compliance Assurance Process
PPC was not a participant in the IRS Compliance Assurance Process ("CAP") for any of the tax years at issue (2017–2020). Accordingly, PPC's transfer pricing positions were not subject to any pre-filing or real-time review by the IRS prior to the commencement of this examination.
III. IDR RESPONSE ACTIVITY — Q3 2022
A. Summary of IDRs Received and Responded To
The IDR response phase has been the primary focus of the defense team's activity during Q3 2022. As of September 30, 2022, the IRS has issued a total of twelve (12) Information Document Requests, numbered IDR No. 1 through IDR No. 12. We anticipate that the IRS will ultimately issue approximately 47 IDRs over the full course of the examination through September 2023, based on our experience with large-case transfer pricing examinations of comparable scope and complexity.
During Q3 2022, C&H prepared and submitted responses to IDRs 1 through 10. Work was in progress on IDRs 11 and 12 as of the close of the quarter, with responses anticipated in early Q4 2022. All IDR responses have been addressed to Lead Revenue Agent Patricia Dunleavy and reference IRS Exam Team ID LB&I-NE-TP-2022-00641 and PPC Employer Identification Number 22-3741856.
C&H's approach to IDR responses has been guided by the principles established in the defense strategy memorandum issued July 12, 2022: responses are thorough, accurate, and timely, but are carefully crafted to avoid volunteering information beyond the scope of each request. All documents produced in IDR responses are first reviewed for potential privilege issues, and a privilege log is being maintained for any documents withheld from production. Each response is reviewed by Mr. Cross or Mr. Simmons prior to submission to the IRS.
B. Key IDR Responses Submitted During Q3 2022
The following summarizes the substance and status of each IDR response completed or in progress during Q3 2022:
IDR No. 1 — Corporate Structure and Organizational Charts Response Submitted: July 8, 2022
IDR No. 1 requested PPC's global corporate organizational charts, entity structures, and ownership diagrams for all affiliated entities relevant to the transfer pricing issues under examination. C&H's response included comprehensive organizational charts depicting PPC's global corporate structure, with particular emphasis on the chain of ownership from PPC through PHL to PBI and PMI. The response also included entity formation documents and a narrative description of each entity's principal activities, jurisdiction of organization, and role within the PPC group. The organizational charts were prepared in collaboration with PPC's internal tax department and were reviewed for accuracy by Mr. Whitfield prior to submission.
IDR No. 2 — Cost-Sharing Arrangement Agreement and Amendments Response Submitted: July 15, 2022
IDR No. 2 requested the complete text of the cost-sharing arrangement between PPC and PBI, together with all amendments, supplements, and side agreements. C&H produced the original CSA agreement dated effective July 1, 2012, along with all subsequent amendments executed through December 31, 2020. The response was accompanied by a cover letter prepared by Mr. Simmons explaining the structural framework of the CSA, the scope of intangible development activities covered by the arrangement, and the methodology for computing each participant's cost-sharing percentage based on reasonably anticipated benefits. The cover letter was carefully drafted to present the CSA in its most favorable light while remaining fully accurate.
IDR No. 3 — Legacy IP License Agreement Response Submitted: July 22, 2022
IDR No. 3 requested the intercompany license agreement governing PBI's use of legacy pharmaceutical compounds. C&H produced the intercompany license agreement between PPC and PBI for legacy compounds, under which PBI pays a royalty rate of 4.5% of net sales for non-Americas territory sales. The response included all schedules and exhibits to the license agreement, including the schedule of covered compounds and the definition of "net sales" used for royalty computation purposes.
IDR No. 4 — Transfer Pricing Documentation (TY 2017–2020) Response Submitted: August 1, 2022
IDR No. 4 requested PPC's contemporaneous transfer pricing documentation for all four tax years under examination. C&H produced the complete transfer pricing documentation reports prepared by Crestfield & Associates LLP for tax years 2017, 2018, 2019, and 2020. These documentation reports were prepared under the standards established by IRC § 6662(e) and Treasury Regulation §§ 1.482-4 and 1.482-7, and are designed to serve as the foundation for PPC's penalty-protection defense under IRC § 6662(e)(3)(B). The documentation addresses PPC's selection and application of the best method for each controlled transaction, the comparability analysis supporting the arm's-length nature of the intercompany pricing, and the economic analysis supporting the CSA cost-sharing percentages and the legacy IP royalty rate.
IDR No. 5 — PCT Valuation and Supporting Workpapers Response Submitted: August 10, 2022
IDR No. 5 requested the original platform contribution transaction valuation report and all supporting workpapers documenting the $312 million PCT payment made by PBI upon entry into the CSA in 2012. C&H produced the original PCT valuation report, which was prepared at the time the CSA was established, together with all supporting financial projections, discount rate calculations, and workpapers. The PCT valuation employed an income-method/DCF approach to value PBI's interest in the pre-existing intangible property at the time of the CSA's effective date. This document is of particular significance because we anticipate the IRS will challenge the PCT payment as undervaluing the pre-existing IP, and the contemporaneous documentation of the valuation methodology and assumptions will be critical to the defense.
IDR No. 6 — R&D Cost Pool and Allocation Methodology Response Submitted: August 18, 2022
IDR No. 6 requested detailed information regarding the composition of the qualified R&D cost pool for each year under examination and the methodology for allocating cost-sharing percentages between PPC and PBI. C&H's response provided a comprehensive breakdown of qualified R&D costs for each tax year:
The response included a detailed narrative explanation of the methodology for determining PBI's reasonably anticipated benefit shares for each year, which are based on projected revenue splits between the Americas and non-Americas territories. The increasing trend in PBI's cost-sharing percentage reflects the growing share of PPC's global revenue derived from non-Americas markets during the 2017–2020 period. The response was prepared in close coordination with Susan Lam at Crestfield, who provided the underlying workpapers and allocation schedules.
IDR No. 7 — PBI Financial Statements and Tax Returns Response Submitted: August 25, 2022
IDR No. 7 requested PBI's statutory financial statements and Irish tax returns for tax years 2017 through 2020. C&H produced PBI's Irish statutory financial statements as filed with the Companies Registration Office for each year, together with PBI's Irish corporate tax returns as filed with Irish Revenue. PBI's financial statements for fiscal year 2020 reported revenue of approximately €2.14 billion and pre-tax income of approximately €1.06 billion. The response included a summary of PBI's effective tax rate for each year, noting that PBI claimed benefits under Ireland's Knowledge Development box beginning in fiscal year 2016, resulting in an effective rate of 6.25% on qualifying income from qualifying IP assets, with the balance of PBI's trading income taxed at the standard Irish rate of 12.5%. Coordination with Thornbury & Keogh in Dublin was required to assemble and verify the completeness of the Irish Revenue filings.
IDR No. 8 — PBI Personnel and Headcount Data Response Submitted: September 5, 2022
IDR No. 8 requested detailed information regarding PBI's personnel, including headcount data over time, organizational charts, and role descriptions for key employees. C&H's response documented PBI's headcount growth from 52 employees at inception in 2012 to 185 employees as of year-end 2020. The response included PBI's internal organizational charts, detailed role descriptions for all senior and mid-level personnel, and a biographical summary for Managing Director Aidan Naughton. The response highlighted PBI's functional depth across regulatory affairs, medical affairs, commercial strategy, pricing and market access, and supply chain management — all of which are critical to establishing PBI's economic substance and its performance of key DEMPE functions for the non-Americas territory.
IDR No. 9 — PBI Board Minutes and Governance Documents Response Submitted: September 12, 2022
IDR No. 9 requested PBI's board of directors meeting minutes and governance documents for the period 2017 through 2020. C&H produced minutes from 42 PBI board meetings held during the examination period, comprising quarterly meetings and special sessions, all of which were held in Dublin, Ireland. The response also included PBI's articles of association, board composition records, committee charters, and other governance documents. The PBI board minutes are significant to the defense because they document PBI's independent decision-making on pricing, market entry, regulatory submissions, capital expenditures, and other strategic matters — evidence that is directly relevant to establishing PBI's economic substance and its autonomous performance of DEMPE functions.
IDR No. 10 — Intercompany Manufacturing Agreement (PMI) Response Submitted: September 20, 2022
IDR No. 10 requested the contract manufacturing agreement between PBI and PMI. C&H produced the intercompany manufacturing agreement under which PMI manufactures oncology and immunology biologics for non-Americas markets on a cost-plus 8% basis. The response included all schedules, including product specifications, quality standards, and the cost-plus markup calculation methodology. The cost-plus 8% markup was established based on a benchmarking study of comparable contract manufacturing arrangements in the pharmaceutical industry and is consistent with arm's-length standards under the cost-plus method.
IDR No. 11 — Product Revenue Data by Territory (In Progress)
IDR No. 11 requests detailed product-level revenue data broken down by Americas and non-Americas territories for all four tax years. As of September 30, 2022, PPC's internal finance team is compiling this data for PPC's three principal products:
Comparable data for tax years 2017–2019 is being assembled. We anticipate submitting the response to IDR No. 11 in early October 2022.
IDR No. 12 — PBI Office Lease and Physical Presence Documentation (In Progress)
IDR No. 12 requests documentation establishing PBI's physical presence in Ireland, including office lease agreements and evidence of actual office operations. C&H is assembling documentation of PBI's lease for approximately 18,000 square feet of office space at Sandyford Business Park, Dublin, along with photographs, utility records, and other evidence of physical office presence and day-to-day business operations. We anticipate submitting the response to IDR No. 12 in mid-October 2022.
C. Extension Requests
One extension request was submitted during the quarter. By letter dated September 20, 2022, Mr. Simmons wrote to Lead Revenue Agent Dunleavy requesting a 30-day extension of time to respond to IDR No. 14 (concerning intercompany service fees and the allocation of shared service costs among PPC group entities). The extension request was necessitated by the need to compile detailed service fee allocation data from multiple PPC affiliates and to coordinate with PPC's internal finance team. The IRS granted the extension request without objection.
D. Coordination with Crestfield & Associates LLP
Throughout Q3 2022, C&H has maintained active coordination with Crestfield & Associates LLP, PPC's independent auditor and the original preparer of PPC's contemporaneous transfer pricing documentation. The primary Crestfield contacts for this matter are Martin Ogilvy, CPA (Engagement Partner) and Susan Lam, CPA (Transfer Pricing Partner).
On July 10, 2022, Mr. Simmons sent an initial data request to Ms. Lam requesting copies of all contemporaneous transfer pricing documentation, supporting workpapers, return data, and economic analyses for tax years 2017 through 2020. Crestfield provided these materials promptly, and they formed the foundation for several of the IDR responses described above, including the transfer pricing documentation production (IDR No. 4), the PCT valuation production (IDR No. 5), and the R&D cost pool and allocation methodology response (IDR No. 6).
Follow-up correspondence with Ms. Lam is ongoing regarding additional breakdowns of the R&D cost pool, including the categorization of costs by activity type (basic research, applied research, clinical development, regulatory) and by product line. These data points will be important for evaluating the reasonableness of PBI's cost-sharing percentages and for supporting the CPM/TNMM analysis being conducted by Whitmore Valuation Group.
Crestfield has been cooperative and responsive throughout this process, and we appreciate the professionalism of their engagement team in facilitating the timely preparation of IDR responses.
E. Coordination with Thornbury & Keogh (Irish Tax Advisors)
Ms. Nazari has been coordinating with Ciarán Thornbury, Lead Partner at Thornbury & Keogh, located at 22 Fitzwilliam Square, Dublin 2, D02 YH68, Ireland, on Irish tax aspects of the defense. This coordination is essential because the IRS examination necessarily implicates PBI's Irish tax positions, particularly PBI's Knowledge Development box claims and its characterization of income for Irish tax purposes.
On August 12, 2022, Ms. Nazari sent an initial coordination email to Mr. Thornbury requesting copies of PBI's Irish Revenue filings and all documentation supporting PBI's Knowledge Development box claims. Thornbury & Keogh provided the requested materials in early September 2022, and these materials supported the IDR No. 7 response.
A follow-up request is planned for November 15, 2022 (to be addressed in our Q4 report), requesting additional PBI substance documentation including commercial office lease agreements, employee contracts and payroll records, and Glenmore Bank Ireland plc account records evidencing PBI's independent banking and treasury operations in Ireland.
F. Privilege Log
In accordance with the privilege protocol memorandum established by Mr. Cross on June 10, 2022, C&H is maintaining a comprehensive privilege log listing all documents withheld from production in response to IRS IDRs on the basis of attorney-client privilege and/or the work-product doctrine. The privilege log includes, for each withheld document: a unique document identifier, document description, date, author, recipient(s), and the specific privilege basis for withholding. The privilege log is being maintained in electronic format and is updated with each IDR response cycle.
The privilege protocol memo established clear guidelines for the C&H and PPC teams regarding the handling of privileged communications, including instructions to clearly mark all privileged documents, to avoid commingling privileged and non-privileged information in the same documents where practicable, and to route all substantive communications regarding the examination through C&H to preserve the attorney-client privilege.
IV. LEGAL RESEARCH AND ANALYSIS COMPLETED
During Q3 2022, the C&H team completed a substantial body of legal research addressing the core issues raised by the IRS examination. These memoranda have been prepared as privileged attorney work product and are intended to inform C&H's defense strategy, to identify potential vulnerabilities in PPC's positions, and to provide the analytical foundation for responding to any proposed adjustments that the IRS may ultimately issue. The principal research memoranda completed during the quarter are summarized below.
A. Core Legal Research Memoranda
1. IRC § 482 Arm's-Length Standard and Best Method Rule
Date: July 20, 2022
Authors: Leila Nazari and Garrett Simmons
This memorandum provides a comprehensive analysis of the arm's-length standard under IRC § 482 and Treasury Regulation § 1.482-1(d), including the best method rule that governs the selection of the most reliable transfer pricing methodology for each controlled transaction. The memorandum surveys the relevant regulatory framework, examines applicable case law, and provides a framework for evaluating PPC's selection and application of transfer pricing methodologies for the CSA cost-sharing percentages, the legacy IP royalty rate, and the PCT valuation. This memorandum serves as the foundational legal analysis upon which the more specific research memoranda described below are built.
2. Qualified Cost-Sharing Arrangements Under Treas. Reg. § 1.482-7
Date: August 5, 2022
Author: Leila Nazari
This memorandum analyzes the regulatory requirements for qualified cost-sharing arrangements under the comprehensive regulations promulgated in Treasury Regulation § 1.482-7. The memorandum addresses the requirements for CSA qualification, including the documentary requirements, the rules for computing reasonably anticipated benefit shares, the methods available for valuing PCT payments (income method, acquisition price method, market capitalization method, residual profit split method), and the compliance standards that must be satisfied to maintain CSA qualification. The memorandum evaluates PPC's CSA against each of these requirements and identifies potential areas of vulnerability.
3. Arm's-Length Royalty Rate Under Treas. Reg. § 1.482-4
Date: August 12, 2022
Author: Garrett Simmons
This memorandum examines the legal standards for establishing an arm's-length royalty rate for intangible property under Treasury Regulation § 1.482-4, with particular emphasis on the comparable uncontrolled transaction method. The memorandum analyzes comparability factors specific to pharmaceutical IP licenses, including the nature and stage of development of the licensed intangibles, the exclusivity and territorial scope of the license, the licensee's obligation to bear development risks, and the royalty base and rate structure. The memorandum evaluates the legal defensibility of PPC's 4.5% royalty rate for legacy compounds and identifies the standards that the IRS must satisfy to adjust the rate under IRC § 482.
4. Economic Substance Doctrine and DEMPE Functions
Date: August 18, 2022
Author: Leila Nazari
This memorandum analyzes the economic substance doctrine as applied in the transfer pricing context, with particular focus on the DEMPE framework (Development, Enhancement, Maintenance, Protection, and Exploitation of intangible property) articulated in the OECD Transfer Pricing Guidelines. The memorandum surveys relevant U.S. case law addressing the economic substance of foreign affiliates in transfer pricing disputes and analyzes the extent to which OECD guidelines may be cited as persuasive authority in U.S. proceedings. The memorandum concludes that PBI's substantial personnel, governance activities, regulatory expenditures, and commercial decision-making authority in Dublin strongly support the economic substance of PBI's operations.
5. Impact of TCJA on Transfer Pricing Positions — TY 2017 vs. 2018–2020
Date: August 25, 2022
Author: Leila Nazari
This memorandum analyzes the effect of the Tax Cuts and Jobs Act (effective January 1, 2018) on PPC's transfer pricing exposure across the examination period. The analysis addresses the reduction in the U.S. corporate tax rate from 35% to 21%, the introduction of the GILTI regime under IRC § 951A, and the BEAT provisions under IRC § 59A, and evaluates how these changes affect both the magnitude of potential IRS adjustments and the economic incentives underlying PPC's transfer pricing structure. The memorandum notes that the rate reduction from 35% to 21% significantly reduces the incremental tax cost of any proposed § 482 adjustments for TY 2018–2020 relative to TY 2017, while the GILTI provisions introduce a minimum tax on PBI's income that partially offsets the benefit of PBI's low Irish effective tax rate.
6. IRC § 6662(e) Penalty Protection and Reasonable Cause Defense
Date: September 2, 2022
Author: Garrett Simmons
This memorandum analyzes the contemporaneous documentation requirements under IRC § 6662(e)(3)(B) and the reasonable cause defense available to taxpayers in transfer pricing cases. The memorandum examines the standards for establishing that the taxpayer maintained contemporaneous documentation sufficient to satisfy the "reasonable belief" requirement, the burden of proof applicable in penalty proceedings, and the factors that the IRS and courts consider in evaluating reasonable cause defenses. The memorandum concludes that PPC's Crestfield-prepared contemporaneous transfer pricing documentation should provide a strong foundation for penalty protection, subject to the ultimate resolution of the substantive transfer pricing issues. Mr. Simmons has assigned additional research on this topic to Ms. Nazari for completion in Q4 2022 (assigned October 28, 2022).
7. Altera and Harborview Corporation Case Analysis
Date: September 15, 2022
Authors: Garrett Simmons and Leila Nazari
This memorandum examines the holdings and reasoning of two landmark transfer pricing decisions and their applicability to PPC's positions. With respect to Altera Corp. v. Commissioner, 941 F.3d 1200 (9th Cir. 2019), the memorandum analyzes the Ninth Circuit's holding that Treasury Regulation § 1.482-7A(d)(2), which requires the inclusion of stock-based compensation costs in the CSA cost pool, is a valid exercise of regulatory authority. The memorandum evaluates whether PPC's R&D cost pool appropriately includes stock-based compensation costs. With respect to Harborview Corporation, Inc. v. Commissioner, 900 F.3d 610 (8th Cir. 2018), the memorandum analyzes the Eighth Circuit's decision regarding the CUT methodology and the appropriate evidentiary standards for establishing comparability of uncontrolled transactions in the medical device and pharmaceutical context. The memorandum identifies specific aspects of the Harborview Corporation analysis that are favorable to PPC's defense, particularly with respect to the use of comparable license agreements to support the legacy IP royalty rate.
8. IRC § 367(d) Outbound IP Transfer Considerations
Date: September 28, 2022
Author: Leila Nazari
This memorandum analyzes whether the IRS might seek to recharacterize the CSA structure as an outbound transfer of intangible property subject to IRC § 367(d), rather than a cost-sharing arrangement subject to IRC § 482 and Treasury Regulation § 1.482-7. The memorandum examines the interplay between § 367(d) and § 482, the conditions under which the IRS has historically invoked § 367(d) in the CSA context, and the legal standards for recharacterization. The memorandum concludes that while a § 367(d) recharacterization is theoretically possible, PPC's CSA structure and documentation are consistent with the requirements for qualification as a QCSA under Treasury Regulation § 1.482-7, which should provide a strong basis for resisting any attempted recharacterization.
B. Additional Research Memoranda
In addition to the core research memoranda described above, the following supplemental analyses were completed or substantially advanced during Q3 2022:
IRS IDR Enforcement Procedures (August 2022, by Nazari). This memorandum analyzed IRS internal procedures for IDR enforcement, including the escalation process from informal follow-up through formal IDR enforcement letters, pre-summons letters, and summons enforcement under IRC § 7602. The memorandum also addressed strategies for managing IDRs that are overbroad, unduly burdensome, or that seek privileged materials, including the process for raising objections and negotiating narrowed IDR scope with the examination team.
CSA Agreement Analysis — Key Terms and Compliance (July 2022, by Simmons). This memorandum analyzed the operative provisions of the CSA agreement effective July 1, 2012, evaluating each key term against the requirements of Treasury Regulation § 1.482-7 for qualification as a QCSA. The analysis addressed the scope of covered intangibles, the definition of intangible development activities, the cost-sharing allocation methodology, the PCT payment terms, the buy-in/buy-out provisions, and the administrative and documentary compliance requirements.
Legacy IP License Agreement Analysis — Royalty Rate and Terms (July 2022, by Nazari). This memorandum analyzed the terms of the intercompany license agreement for legacy compounds, including the 4.5% royalty rate, the royalty base definition, the territorial scope, and the duration and termination provisions, evaluating each against the arm's-length standards of Treasury Regulation § 1.482-4 and applicable comparability factors.
PMI Contract Manufacturing Agreement Analysis — Cost-Plus 8% (August 2022, by Nazari). This memorandum analyzed the PBI-PMI contract manufacturing agreement and evaluated the cost-plus 8% markup for arm's-length compliance under the cost-plus method prescribed by Treasury Regulation § 1.482-3(d). The analysis included a review of the cost base definition, the markup percentage, and comparability with industry benchmarks for contract pharmaceutical manufacturers.
PHL Entity Classification and Structure (July 2022, by Nazari). This memorandum analyzed PHL's entity classification as a disregarded entity for U.S. federal income tax purposes under the check-the-box regulations of Treasury Regulation § 301.7701-3, and evaluated PHL's role as an intermediate holding company in the PPC group structure. The memorandum addressed the implications of PHL's disregarded status for the transfer pricing analysis and for the IRS's potential adjustment theories.
V. FUNCTIONAL ANALYSIS AND ECONOMIC WORK — WHITMORE VALUATION
A. Kovel Engagement Status
The Kovel engagement letter with Whitmore Valuation Group LLC was executed on June 20, 2022 (reference number 1018-00009-KV). Whitmore's offices are located at 200 Ashbury Asset Advisors, Suite 700, Boston, Massachusetts 02109. The engagement is structured as a Kovel arrangement to ensure that the economic analyses prepared by Whitmore in connection with C&H's representation of PPC are protected under the attorney-client privilege and the work-product doctrine. Under this arrangement, Whitmore is retained by and reports to C&H, and all substantive communications regarding the engagement are directed through the C&H legal team.
The lead economist assigned to the engagement is Dr. Helena Vasquez, Managing Director at Whitmore Valuation Group, who has extensive experience in transfer pricing economics for pharmaceutical and biotechnology companies. Dr. Vasquez is supported by Dr. Rohan Chakrabarti, Senior Director, who is responsible for the day-to-day economic analysis and benchmarking work. The blended hourly rate for Whitmore's services under the engagement is $650 per hour.
Mr. Cross sent the engagement kickoff email to Dr. Vasquez on June 21, 2022, outlining the scope of the economic analyses to be performed, the initial data requirements, and the target timeline for deliverables. Since that time, regular coordination calls have been held between the C&H team and the Whitmore team, typically on a biweekly basis, to review progress, address data needs, and discuss analytical approaches.
B. Work Completed and In Progress
Functional Analysis of PBI (Target Completion: October 2022)
Whitmore is preparing a comprehensive functional analysis documenting PBI's functions, assets, and risks during the 2017–2020 period. This analysis is a critical element of the defense because it will establish the factual foundation for PBI's economic substance and its performance of key DEMPE functions in the non-Americas territory. The functional analysis covers PBI's regulatory affairs activities (including interactions with the European Medicines Agency and national regulatory authorities), commercial strategy and pricing activities across 68 country markets, medical affairs and scientific communications activities, supply chain management, and overall governance and strategic decision-making. The analysis documents PBI's 185 employees as of 2020, the 42 board meetings held in Dublin during the examination period, PBI's cumulative regulatory expenditures of approximately €47.2 million during 2017–2020, and PBI's independent pricing and market access activities across its territory. A draft of the functional analysis is expected by the end of October 2022.
PBI Personnel Interviews (Completed August–September 2022)
During August and September 2022, Mr. Simmons and Ms. Nazari traveled to Dublin to conduct in-person interviews with twelve (12) key PBI employees. These interviews were conducted under the direction of C&H and are protected as attorney work product. The interviews documented each employee's role and responsibilities, their decision-making authority, their interactions with PPC personnel in the United States, and their functional contributions to PBI's non-Americas commercialization activities. Detailed interview summaries have been prepared by Ms. Nazari and are being incorporated into the functional analysis. The interviewees included PBI's Managing Director, heads of regulatory affairs, commercial strategy, medical affairs, supply chain, and finance, as well as several senior managers in key functional areas.
PBI Board Minutes Analysis (Completed September 2022)
Ms. Nazari has completed a comprehensive analysis cataloguing and analyzing the substance of all 42 PBI board meetings held in Dublin during the 2017–2020 period. This analysis identifies and categorizes the key decisions made at each meeting, including decisions related to product pricing in specific markets, market entry strategies for new country approvals, regulatory submission authorizations, capital expenditure approvals, key personnel appointments, and commercial partnerships. This analysis is designed to demonstrate that PBI's board exercised genuine, independent decision-making authority over PBI's business operations, rather than merely rubber-stamping decisions made at the U.S. parent level.
CUT Analysis (Royalty) — In Progress (Target Completion: November 2022)
Whitmore is conducting a CUT analysis to identify comparable uncontrolled pharmaceutical license agreements that can be used to support the arm's-length nature of PPC's 4.5% legacy IP royalty rate. The analysis involves searching proprietary databases (including Vireo Health IT, Sundial Health IT, and SEC filings) for license agreements involving comparable pharmaceutical intangible property with comparable territorial scope, exclusivity provisions, and licensee obligations. Dr. Vasquez and Dr. Chakrabarti are applying detailed screening criteria to identify the most reliable comparable transactions and are conducting comparability adjustments where appropriate. The target completion date for the CUT analysis is November 2022.
CPM/TNMM Analysis (CSA) — In Progress (Target Completion: November 2022)
Whitmore is conducting a CPM/TNMM analysis testing PBI's operating margins against a set of comparable companies to evaluate the arm's-length nature of the intercompany pricing resulting from the CSA. The analysis involves identifying comparable independent distributors and IP-holding companies in the pharmaceutical industry using the Bureau van Dijk and Fenmore Services Inc. databases, applying quantitative and qualitative screening criteria, and computing arm's-length ranges of operating margins using appropriate profit level indicators. Target completion is November 2022.
PCT Valuation / DCF Analysis — In Progress (Target Completion: December 2022)
Whitmore is preparing an independent revaluation of the PCT payment using an income-method/DCF approach. The purpose of this analysis is to confirm the reasonableness of the original $312 million PCT payment and to provide an independent economic basis for defending the PCT valuation against any IRS challenge. Whitmore's preliminary analysis indicates that an appropriate weighted average cost of capital ("WACC") for the DCF valuation is approximately 9.8%, which reflects the risk profile of PBI's business and the uncertainty inherent in pharmaceutical revenue projections at the time of the CSA's effective date. We anticipate that the IRS, through its economist Dr. Washburne, will argue for a lower discount rate, which would result in a higher present value of projected benefits and, correspondingly, a higher PCT payment. The choice of discount rate is likely to be a significant point of contention in the examination. Target completion for the PCT/DCF analysis is December 2022.
Benchmarking Study — In Progress
An Excel workbook is being compiled by the Whitmore team containing all search criteria, screening results, and financial data for the CUT and CPM/TNMM comparable sets. This workbook will serve as the underlying data repository supporting the economic analyses and will be available for review by the IRS if and when the economic reports are shared during the examination or Appeals process.
discount Rate / WACC Analysis — In Progress (Target Completion: December 2022)
As noted above, the appropriate discount rate for the PCT/DCF valuation is expected to be a key area of dispute. Whitmore is preparing a detailed WACC analysis documenting the derivation of the approximately 9.8% discount rate, including the inputs for cost of equity (using the capital asset pricing model), cost of debt, capital structure assumptions, and any applicable risk premia.
C. DEMPE Functions Matrix
Work has commenced on the preparation of a comprehensive DEMPE functions matrix that will document the allocation of Development, Enhancement, Maintenance, Protection, and Exploitation functions between PPC (United States) and PBI (Ireland) for each key product line — Veritaxol, Imvara, and Cerulon. The matrix will be supported by headcount data, expenditure data, and qualitative descriptions of each function, and will demonstrate that PBI performs substantial DEMPE functions in Ireland that justify the economic returns allocated to PBI under the CSA and royalty arrangements. The DEMPE matrix will draw upon the functional analysis, the PBI personnel interviews, the board minutes analysis, and the regulatory expenditure records assembled during Q3 2022.
VI. FIN 48 / ASC 740-10 RESERVE ANALYSIS
Mr. Cross and Mr. Simmons completed a memorandum dated September 2022 providing C&H's legal analysis in support of PPC's uncertain tax position reserve under ASC 740-10 (formerly FIN 48) related to PPC's Irish IP-holding structure and transfer pricing positions. The memorandum analyzed PPC's transfer pricing positions under the two-step framework prescribed by ASC 740-10: first, the "more-likely-than-not" recognition threshold (i.e., whether it is more likely than not that PPC's transfer pricing positions will be sustained upon examination based on their technical merits); and second, the measurement step (i.e., the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement).
The analysis considered the strength of PPC's contemporaneous transfer pricing documentation, the economic analysis supporting the CSA cost-sharing percentages and the legacy IP royalty rate, PBI's economic substance, and the applicable case law and regulatory framework. Based on this analysis, C&H concluded that PPC's existing reserve of $62.4 million is adequate as of the balance sheet date, given the current stage of the examination and C&H's assessment of the defensibility of PPC's transfer pricing positions.
By letter dated September 20, 2022, Mr. Cross provided a copy of C&H's legal analysis to Martin Ogilvy, CPA, Engagement Partner at Crestfield & Associates LLP, for purposes of supporting PPC's financial statement disclosures related to the uncertain tax position reserve. The letter confirmed C&H's assessment that the $62.4 million reserve is adequate under the current circumstances, while noting that the analysis will be updated as the examination progresses and the IRS's specific adjustment theories become clearer.
We emphasize that the adequacy of the FIN 48 reserve will need to be re-evaluated at each reporting date as the examination develops, and particularly after the IRS issues any proposed adjustments or a NOPA. We will work with PPC's tax department and with Crestfield to ensure that reserve levels are adjusted as appropriate in light of new information.
VII. IRS EXAMINATION OBSERVATIONS AND PRELIMINARY ASSESSMENT
A. IRS Focus Areas Observed
Based on the patterns of IDR requests received during Q3 2022, the substance of the opening conference held on June 28, 2022, and our experience with the IRS LB&I transfer pricing practice, we have identified the following as the IRS examination team's primary areas of focus:
1.  CSA Structure and Cost-Sharing Ratios. The IRS has devoted significant attention to the CSA agreement itself, the methodology for computing PBI's cost-sharing percentages, and the composition of the R&D cost pool. The detailed requests for cost pool data and allocation methodology (IDR No. 6) and product-level revenue data by territory (IDR No. 11) are consistent with an IRS challenge to PPC's reasonably anticipated benefit projections and the resulting cost-sharing ratios.
2.  Legacy IP Royalty Rate. The IRS's request for the legacy IP license agreement (IDR No. 3) and the contemporaneous transfer pricing documentation (IDR No. 4) indicate a focus on the 4.5% royalty rate. Based on our experience, the IRS is likely developing its own CUT analysis to identify comparable license transactions that it believes support a higher royalty rate.
3.  PCT Valuation. The request for the PCT valuation report and supporting workpapers (IDR No. 5) confirms the IRS's interest in the $312 million PCT payment. The IRS frequently challenges PCT payments as undervaluing the pre-existing IP contributed to cost-sharing arrangements, and we anticipate a similar challenge here.
4.  PBI Economic Substance and DEMPE Functions. The requests for PBI personnel data (IDR No. 8), board minutes (IDR No. 9), and physical presence documentation (IDR No. 12) indicate that the IRS is evaluating whether PBI has sufficient economic substance to justify the income allocated to it under the transfer pricing structure, and whether key DEMPE functions remained in the United States rather than being genuinely performed by PBI in Ireland.
Mr. Cross communicated these strategic observations to Ms. Hartwell in a memorandum dated October 5, 2022, noting the IRS examination team's apparent particular focus on the royalty rate and PBI substance issues. These observations inform our defense strategy and the prioritization of our legal research and economic analysis work.
The identification of IRS Economist Dr. Alan Washburne as a member of the examination team is significant. His presence confirms that the IRS is conducting its own independent economic analysis of PPC's transfer pricing positions. We anticipate that Dr. Washburne will develop the IRS's own comparable transaction set for the CUT analysis, conduct independent testing of PBI's operating margins under the CPM/TNMM, and may challenge the discount rate and revenue projections used in PPC's PCT valuation. His involvement underscores the importance of ensuring that Whitmore's independent economic analyses are rigorous and well-supported.
B. Anticipated IRS Positions (Preliminary)
Based on the initial assessment memorandum prepared by C&H on June 15, 2022, and developments during Q3 2022, we have identified the following anticipated IRS positions:
CSA Cost-Sharing Ratios. The IRS may challenge PPC's methodology for computing PBI's reasonably anticipated benefit shares, asserting that PPC's revenue projections understate the relative value of U.S.-source benefits and overstate the relative value of non-Americas benefits. An upward adjustment to PPC's benefit share would reduce PBI's cost-sharing percentage and increase PBI's royalty or other payments to PPC.
Legacy IP Royalty Rate. The IRS may challenge the 4.5% royalty rate as inadequate compensation for the use of legacy pharmaceutical IP in the non-Americas territory. The IRS may develop its own CUT analysis identifying comparable license agreements with higher royalty rates and may argue that adjustments to PPC's comparable set are required to account for differences in the value of the licensed intangibles, the territorial scope, or other comparability factors.
PCT Payment. The IRS may assert that the $312 million PCT payment undervalues the pre-existing IP that PBI acquired rights to upon entry into the CSA in 2012. The IRS may argue for a lower discount rate (resulting in a higher present value) or may challenge PPC's revenue projections as too conservative. An increased PCT payment would generate additional U.S. taxable income for PPC in 2012 (or would be amortized over the useful life of the IP for tax purposes, depending on the IRS's characterization).
Economic Substance of PBI. The IRS may challenge PBI's economic substance, arguing that key decision-making authority and DEMPE functions remained in the United States and that PBI was merely a conduit for diverting income from the U.S. tax base. If successful, this argument could support a reallocation of income from PBI to PPC under IRC § 482.
We emphasize that no proposed adjustments or NOPA have been issued at this stage, and these anticipated positions are based on our experience and analysis of the IRS's examination patterns. The actual IRS positions may differ from these preliminary assessments as the examination develops.
We currently anticipate that the examination will continue through 2023, with a NOPA potentially issuing in mid-to-late 2023, based on the current pace of IDR issuance and our assessment of the remaining information the IRS will need to gather before formulating its adjustment positions.
C. Defense Strategy Status
The defense strategy memorandum was issued by Mr. Cross and Ms. Hartwell to Mr. Whitfield, Ms. Staines, and Mr. Iyer on July 12, 2022. The memorandum outlined a three-phase defense plan:
Phase 1 — IDR Response Phase (current phase): Responsive and thorough cooperation with the IRS examination team; proactive development of legal and economic defense positions; preservation of all defense-relevant documents and privilege protections.
Phase 2 — NOPA/Protest Phase (anticipated 2023): Review and analysis of any NOPA issued by the IRS; preparation and filing of a comprehensive Protest with the IRS Appeals Office; coordination of economic rebuttal evidence.
Phase 3 — Appeals Phase (anticipated 2024): Representation of PPC before IRS Appeals; negotiation of potential settlement; evaluation of litigation alternatives if Appeals resolution is not achieved.
We remain in Phase 1 of the defense plan. The following defensive measures have been implemented:
Document Preservation Notice. A document preservation notice was issued on June 6, 2022, directing the preservation of all documents and electronically stored information potentially relevant to the IRS examination by PPC, PBI, PHL, and PMI. The preservation notice covers email, financial records, board minutes, intercompany agreements, transfer pricing studies, R&D records, personnel files, and all other potentially relevant categories of documents.
Privilege Protocol. A privilege protocol memorandum was established by Mr. Cross on June 10, 2022, governing the handling of privileged communications and work product throughout the engagement. The protocol establishes guidelines for marking privileged documents, maintaining the privilege log, and ensuring that privileged materials are not inadvertently disclosed in IDR responses.
Intercompany Agreement Matrix. An intercompany agreement matrix is being compiled, cataloguing all intercompany agreements within the PPC group that are relevant to the examination. The matrix includes the CSA, the legacy IP license agreement, the PMI contract manufacturing agreement, intercompany service agreements, and any other agreements that govern the pricing of controlled transactions. For each agreement, the matrix identifies the parties, effective date, subject matter, pricing methodology, and relevant regulatory authority.
VIII. BUDGET AND FEE STATUS
A. Calderwood & Harkness LLP Fees
Original Estimated Fee Range. As set forth in the engagement letter dated June 2, 2022, and as further detailed in the budget estimate prepared for Mr. Whitfield in June 2022, C&H's estimated fee range for the complete representation of PPC through Appeals resolution is $4.5 million to $7.0 million. This estimate encompasses all three phases of the defense plan (IDR Response, NOPA/Protest, and Appeals) and is subject to adjustment based on the scope and complexity of the IRS's adjustments and the duration of the Appeals process.
2022 Billing Rates. The following standard hourly rates apply to the C&H professionals staffed on this matter for 2022:
Q3 2022 Fees Billed. During Q3 2022, C&H billed fees totaling approximately $487,600 for work performed during the quarter. This amount reflects the intensive activity associated with the initial IDR response phase, the commencement of the legal research program, and the coordination of economic analysis work with Whitmore Valuation Group. The Q3 fees break down approximately as follows by timekeeper category: Mr. Cross (approximately 68 hours — strategy development, IRS correspondence, client management, opening conference preparation and attendance); Ms. Hartwell (approximately 22 hours — client management, billing oversight, strategic input on defense plan); Mr. Simmons (approximately 245 hours — IDR response coordination, economic analysis coordination with Whitmore, drafting of legal research memoranda, PBI personnel interviews); Ms. Nazari (approximately 198 hours — legal research, document production, Irish coordination with Thornbury & Keogh, PBI personnel interviews, privilege log maintenance); and paralegal staff (approximately 85 hours — document production, privilege log, organizational support).
Year-to-Date 2022 Fees Billed. Year-to-date fees billed through September 30, 2022, total approximately $612,300, reflecting the Q3 activity described above as well as the engagement setup, Form 2848 filing, opening conference preparation, and initial document review work performed in June 2022. The year-to-date total is well within the budget expectations for Phase 1 activity through this point in the engagement.
Detailed Billing Summary. A detailed breakdown by timekeeper, with narrative task descriptions, is maintained in the billing summary workbook for Matter 1018-00009. Copies of the detailed billing statements are provided to Mr. Whitfield under separate cover on a monthly basis.
B. Whitmore Valuation Group LLC Fees
Blended Rate. The Kovel engagement p